| Clone: | EBVCS-5 |
|---|---|
| Isotype: | Mouse IgG1 |
| Specificity: | The mouse monoclonal antibody EBVCS-5 recognizes an epitope located in the stalk region of human low affinity IgE receptor (CD23) between the 37 and 25 kDa cleavage sites. |
| Immunogen: | EBV-transformed human cells |
| Species Reactivity: | Human |
| Preparation: | The purified antibody is conjugated with R-Phycoerythrin (PE) under optimum conditions. The conjugate is purified by size-exclusion chromatography and adjusted for direct use. No reconstitution is necessary. |
| Storage Buffer: | The reagent is provided in phosphate buffered saline (PBS) containing 15 mM sodium azide and 0.2% (w/v) high-grade protease free Bovine Serum Albumin (BSA) as a stabilizing agent. |
| Storage / Stability: | Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label. Short-term exposure to room temperature should not affect the quality of the reagent. However, if reagent is stored under any conditions other than those specified, the conditions must be verified by the user. |
| Usage: | The reagent is designed for Flow Cytometry analysis of human blood cells using 10 μl reagent / 100 μl of whole blood or 106 cells in a suspension. The content of a vial (0.25 ml) is sufficient for 25 tests. |
| Expiration: | See vial label |
| Lot Number: | See vial label |
| Background: | CD23 (Fc epsilon RII), the low affinity IgE receptor, is a 45 kDa type II membrane glycoprotein expressed more or less on eosinophils, follicular dendritic cells, Langerhans cells, mature B cells (mainly upon activation), EBV-transformed lymphoblasts, monocytes, and subpopulation of platelets. A soluble form of 37 kDa and other its fragments were also described. CD23 mediates IgE-dependent cytotoxicity by eosinophils and macrophages, and downregulates IgE secretion in response to high levels of IgE, involving release of pro-inflammatory cytokines. |
| References: |
*Ling NR, Stevenson FK, Brown B: Urinary excretion of CD23 antigen in normal individuals and patients with chronic lymphocytic leukaemia (CLL). Clin Exp Immunol. 1991 Dec;86(3):360-6.
*Yamaoka KA, Arock M, Issaly F, Dugas N, Le Goff L, Kolb JP: Granulocyte macrophage colony stimulating factor induces Fc epsilon RII/CD23 expression on normal human polymorphonuclear neutrophils. Int Immunol. 1996 Apr;8(4):479-90.
*Belleau JT, Gandhi RK, McPherson HM, Lew DB: Research upregulation of CD23 (FcepsilonRII) expression in human airway smooth muscle cells (huASMC) in response to IL-4, GM-CSF, and IL-4/GM-CSF. Clin Mol Allergy. 2005 May 20;3:6.
*Byrd JC, O'Brien S, Flinn IW, Kipps TJ, Weiss M, Rai K, Lin TS, Woodworth J, Wynne D, Reid J, Molina A, Leigh B, Harris S: Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4448-55.
*Rumi C, Rutella S, Leone G, Bonini S: Fc-RII/CD23 receptor on circulating human eosinophils. Blood. 1998 Apr 1;91(7):2621-2.
|
For laboratory research only, not for drug, diagnostic or other use. EXBIO Praha | Nad Safinou II 341 | 252 42 Vestec u Prahy | Czech Republic Tel: +420 261 090 664 | Fax: +420 261 090 660 | orders@exbio.cz | www.exbio.cz |